How are payers responding when costly gene therapies don’t deliver long-term durability? We explore evolving contract models tackling buyer’s remorse in cell and gene therapy.

Turkey's new alternative reimbursement legislation aims to modernize its healthcare sector by promoting innovative contracting. It eases interactions with international pharmaceutical companies, ensures price confidentiality, and expedites product launches. However, Omar notes that companies are turning to these alternative methods due to challenges with Turkey's traditional reimbursement model, including high discounting rates. This shift is driving companies to develop more innovative contracting proposals for this alternative route.